Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

BACKGROUND/AIM: Post-progression treatment following tyrosine-kinase inhibitor (TKI) failure in patients with unresectable hepatocellular carcinoma (u-HCC) is important to prolong post-progression survival (PPS), which has a good correlation with overall survival (OS). This study aimed to elucidate...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Liver Cancer
Main Authors: Hiraoka, Atsushi, Kumada, Takashi, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Yokohama, Keisuke, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi
פורמט: Artigo
שפה:Inglês
יצא לאור: S. Karger AG 2020
נושאים:
Original Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7024896/
https://ncbi.nlm.nih.gov/pubmed/32071911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503031
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים